PCH: Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System
What it covers
A gastrointestinal pathogen panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple gastrointestinal microbial nucleic acids extracted from human stool specimens. The detection and identification of a specific gastrointestinal microbial nucleic acid from individuals exhibiting signs and/or symptoms of gastrointestinal infection aids in the diagnosis of gastrointestinal infection when used in conjunction with clinical evaluation and other laboratory findings.
FDA’s definition of product code PCH, from the Product Classification database.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K253722 | LIAISON PLEX Gastrointestinal Flex Assay | Luminex Corporation | May 19, 2026 | Traditional |
| K254032 | QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B | QIAGEN GmbH | Mar 9, 2026 | Traditional |
| K251721 | Xpert GI Panel | Cepheid | Jan 16, 2026 | Traditional |
| K252329 | QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini B | QIAGEN GmbH | Oct 22, 2025 | Traditional |
| K251993 | Panther Fusion GI Expanded Bacterial Assay | Hologic, Inc. | Sep 25, 2025 | Traditional |
| K251868 | Panther Fusion GI Bacterial Assay | Hologic | Sep 25, 2025 | Traditional |
| K250324 | QIAstat-Dx GI Panel 2 Mini B | QIAGEN GmbH | Feb 28, 2025 | Special |
| K243885 | BIOFIRE FILMARRAY Gastrointestinal (GI) Panel Mid | Biofire Diagnostics, LLC | Jan 16, 2025 | Special |
| K242877 | BioCode Gastrointestinal Pathogen Panel (GPP) | Applied BioCode, Inc. | Jan 10, 2025 | Traditional |
| K243813 | QIAstat-Dx GI Panel 2 Mini B&V | QIAGEN GmbH | Jan 8, 2025 | Special |
Clearances by year
38 PCH 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 3 | 176 |
| 2025 | 7 | 89 |
| 2024 | 3 | 271 |
| 2023 | 1 | 29 |
| 2022 | 2 | 205 |
| 2019 | 4 | 191 |
| 2018 | 4 | 105 |
| 2017 | 1 | 90 |
| 2016 | 2 | 105 |
| 2015 | 2 | 184 |
| 2014 | 6 | 120 |
| 2013 | 3 | 89 |
Who submits
16 applicants cleared a PCH device since 2011. 61% of the clearances went to applicants in United States, then Canada (21%), Germany (13%) and Australia (3%). By type: Traditional 74%, Special 24% and Post-NSE 3%.
| Applicant | Clearances since 2011 |
|---|---|
| Luminex Molecular Diagnostics, Inc. | 8 |
| Becton, Dickinson and Company | 5 |
| Biofire Diagnostics, LLC | 5 |
| QIAGEN GmbH | 5 |
| Applied BioCode, Inc. | 3 |
| Cepheid | 2 |
| Biofire Diagnostics | 1 |
| Gen-Probe Prodesse, Inc. | 1 |
How FDA classifies it
Class II (special controls). The special controls are set forth in FDA's guideline document entitled: “Class II Special Controls Guideline: Gastrointestinal Microorganism Multiplex Nucleic Acid-Based Assays for Detection and Identification of Microorganisms and Toxin Genes from Human Stool Specimens.” For availability of the guideline document, see § 866.1(e).
From 21 CFR 866.3990. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 866.3990 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent PCH clearances declared.
Ask about PCH
Questions about PCH
What is FDA product code PCH?
Product code PCH, “Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System” in FDA's classification database, is a Class II device type under 21 CFR 866.3990 (gastrointestinal microorganism multiplex nucleic acid-based assay), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 38 clearances under PCH, 38 of them since 2011.
How many 510(k) clearances are there under PCH?
FDA’s 510(k) database listed 38 clearances under PCH as of Oct 29, 2026, 38 of them decided since 2011; the most recent decision was May 19, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a PCH 510(k)?
For the 11 PCH clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 90 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most PCH clearances?
Since 2011: Luminex Molecular Diagnostics, Inc. (8), Becton, Dickinson and Company (5), Biofire Diagnostics, LLC (5), QIAGEN GmbH (5) and Applied BioCode, Inc. (3). 16 applicants have cleared a PCH device in that time.